Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Mol Autism. 2017 Mar 21;8:14. doi: 10.1186/s13229-017-0130-3. eCollection 2017.

Leveraging blood serotonin as an endophenotype to identify de novo and rare variants involved in autism.

Author information

1
Molecular Physiology & Biophysics, Vanderbilt University, Nashville, TN USA.
2
Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN USA.
3
Division of Genetic Medicine, Department of Medicine, Vanderbilt University, Nashville, TN USA.
4
Department of Psychiatry, University of Illinois at Chicago, Chicago, IL USA.
5
Department of Psychiatry, University of Minnesota, Minneapolis, MN USA.

Abstract

BACKGROUND:

Autism spectrum disorder (ASD) is one of the most highly heritable neuropsychiatric disorders, but underlying molecular mechanisms are still unresolved due to extreme locus heterogeneity. Leveraging meaningful endophenotypes or biomarkers may be an effective strategy to reduce heterogeneity to identify novel ASD genes. Numerous lines of evidence suggest a link between hyperserotonemia, i.e., elevated serotonin (5-hydroxytryptamine or 5-HT) in whole blood, and ASD. However, the genetic determinants of blood 5-HT level and their relationship to ASD are largely unknown.

METHODS:

In this study, pursuing the hypothesis that de novo variants (DNVs) and rare risk alleles acting in a recessive mode may play an important role in predisposition of hyperserotonemia in people with ASD, we carried out whole exome sequencing (WES) in 116 ASD parent-proband trios with most (107) probands having 5-HT measurements.

RESULTS:

Combined with published ASD DNVs, we identified USP15 as having recurrent de novo loss of function mutations and discovered evidence supporting two other known genes with recurrent DNVs (FOXP1 and KDM5B). Genes harboring functional DNVs significantly overlap with functional/disease gene sets known to be involved in ASD etiology, including FMRP targets and synaptic formation and transcriptional regulation genes. We grouped the probands into High-5HT and Normal-5HT groups based on normalized serotonin levels, and used network-based gene set enrichment analysis (NGSEA) to identify novel hyperserotonemia-related ASD genes based on LoF and missense DNVs. We found enrichment in the High-5HT group for a gene network module (DAWN-1) previously implicated in ASD, and this points to the TGF-Ī² pathway and cell junction processes. Through analysis of rare recessively acting variants (RAVs), we also found that rare compound heterozygotes (CHs) in the High-5HT group were enriched for loci in an ASD-associated gene set. Finally, we carried out rare variant group-wise transmission disequilibrium tests (gTDT) and observed significant association of rare variants in genes encoding a subset of the serotonin pathway with ASD.

CONCLUSIONS:

Our study identified USP15 as a novel gene implicated in ASD based on recurrent DNVs. It also demonstrates the potential value of 5-HT as an effective endophenotype for gene discovery in ASD, and the effectiveness of this strategy needs to be further explored in studies of larger sample sizes.

KEYWORDS:

5-HT; Autism; Autism spectrum disorder; Compound heterozygotes; De novo mutation; Endophenotype; Group-wise transmission/disequilibrium test; Hyperserotonemia; Rare variants; Serotonin; Whole exome sequencing

PMID:
28344757
PMCID:
PMC5361831
DOI:
10.1186/s13229-017-0130-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center